Fidelity Disruptive Medicine ETF (FMED) has seen unusual trading volume, which is 36× higher than its average daily volume.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Among FMED’s top holdings, Cogent Biosciences has drawn heavy analyst attention, with multiple firms including H.C. Wainwright, Guggenheim and LifeSci Capital reiterating Buy ratings and lifting or affirming price targets even as the company continues to post sizable GAAP net losses and faces negative insider sentiment. Alnylam Pharmaceuticals also saw upbeat coverage, as Barclays maintained a Buy rating and a sharply higher price target amid a Strong Buy consensus, while mental health provider LifeStance Health Group rallied after reporting a 21% jump in first‑quarter revenue, significantly higher net income, and raising its 2026 outlook. Further down the portfolio, Argenx delivered robust Q1 results with 63% product sales growth, confirmed ambitious long‑term goals, and benefited from a wave of Buy ratings, whereas Bio‑Techne absorbed a series of price‑target cuts from several banks after weaker organic growth and cautious guidance. Insmed reported better‑than‑expected Q1 revenue and highlighted strong momentum for its BRINSUPRI launch and late‑stage pipeline, and UnitedHealth received a reaffirmed Buy rating with a modest upside target, underscoring continued confidence in the healthcare giant within the ETF’s mix.